

ALACHUA, Fla., June 30 /PRNewswire-FirstCall/ -- Regeneration Technologies Inc. (Nasdaq: RTIX - News; RTI), the Florida-based processor of orthopedic, cardiovascular and other allograft implants, announced today that its vice president of business development, C. Randal Mills, Ph.D., has accepted a position as chief executive officer of Osiris Therapeutics Inc. Mills will be leaving RTI as of July 2.

"Leading a company like Osiris meets one of Randy's professional goals and will allow him to use his strengths in scientific innovation and in the business of research," said Brian K. Hutchison, chairman, president and CEO of RTI. "We wish him the best and thank him for his contributions to our company."

As one of the founding employees of RTI, Mills led the team that invented the patented BioCleanse® Tissue Sterilization Process. BioCleanse is the only proven tissue sterilization system validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the allograft. Since March 2000, RTI has distributed almost 500,000 implants sterilized with the BioCleanse process with zero incidence of infection.

Going forward, RTI will continue its focus on industry-leading research and development with a commitment to science, safety and innovation.

"The business development and R&D teams are still very strong. We have some of the top scientists and innovators in the industry at RTI conducting some very exciting research," Hutchison said. "We recently recruited Bill Melendez, formerly of Baxter International, as the executive director of research and development. As promised, this year we are doubling our resources in R&D. This commitment will not change, and RTI will remain a leader in science and innovation."

About Osiris Therapeutics Inc.

Osiris Therapeutics, Inc. is the leader in adult stem cell therapy for regenerative medicine. The stem cell therapies produced by Osiris are derived from volunteer adult donors and are then expanded using our proprietary technology to very high numbers in culture. These remarkable cells can then be used in patients unrelated to the donor, without rejection, eliminating the need for donor matching and recipient immune suppression. Once transplanted, the cells have the ability to repair damaged or diseased tissues. The Company's current focus includes the use of adult stem cells to improve outcomes in bone marrow recipients being treated for cancers such as leukemia, to promote cardiac repair resulting from a heart attack or congestive heart failure, and prevention and treatment of arthritis.

About Regeneration Technologies, Inc.

RTI processes allograft tissue into shaped implants for use in orthopedic, cardiovascular and other surgeries with a commitment to science, safety and innovation. By processing allograft tissue into forms that can be used in many types of surgical procedures, RTI enables patients to benefit from the gift of donated tissues. RTI is accredited by the American Association of Tissue Banks and was named a 2004 Technology Pioneer by the World Economic Forum.